Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
Clinical trial NCT07739888 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07739888
- Sponsor
- Novartis Pharmaceuticals
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2027-12-30
- Primary completion
- 2030-12-30
- Enrollment
- 2500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.